Prospective Familial Registry for Pancreas Research
PARTNER
Prospective Familial Cohort for Pancreas Research
1 other identifier
observational
3,000
1 country
1
Brief Summary
The purpose of this research is to develop a resource registry of individuals currently without pancreatic cancer but are members of a kindred with two or more blood-related family members with pancreas cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2026
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 5, 2026
CompletedStudy Start
First participant enrolled
January 5, 2026
CompletedFirst Posted
Study publicly available on registry
January 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2040
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2040
January 22, 2026
January 1, 2026
14.8 years
January 5, 2026
January 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
To establish a prospective cohort of individuals from pancreas cancer families
To establish and actively follow a resource registry of individuals currently without pancreatic cancer but are members of a kindred with two or more blood-related family members with pancreas cancer.
25 years
Change in health
Participants will be asked to complete a health questionnaire every 2 years to ascertain new cancer diagnosis in the subject and in first-degree relatives.
25 years
Study Arms (1)
Family history of pancreas cancer
Prospective cohort of individuals who do not have pancreas cancer but are members of a kindred with two or more blood-related family members with pancreas cancer, or with at least one blood-related family member with pancreas cancer and one relative who carries a variant in a gene known to be associated with pancreatic cancer.
Eligibility Criteria
US citizens who meet eligibility requirements
You may qualify if:
- An individual who was previously enrolled in Mayo Clinic IRB # 1197-00, 354-06, 355-06, or 19-010791
- Is age 18 years or older.
- Has a valid United States mailing address.
- Has at least two blood-related relatives who have had pancreas cancer or has a blood-relative with pancreatic cancer and that relative carries a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53 or mutations in other genes known to be associated with pancreatic cancer.
You may not qualify if:
- An individual who is a prison inmate
- An individual who is not compos mentis (of sound mind, memory, and understanding), and not able to give consent.
- Has personal history of pancreas cancer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Mayo Clinic
Rochester, Minnesota, 55905, United States
Related Links
Biospecimen
One-time specimen up to 50cc
Study Officials
- PRINCIPAL INVESTIGATOR
Samuel Antwi, Ph.D.
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 25 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 5, 2026
First Posted
January 22, 2026
Study Start
January 5, 2026
Primary Completion (Estimated)
November 1, 2040
Study Completion (Estimated)
November 1, 2040
Last Updated
January 22, 2026
Record last verified: 2026-01